Stock Analysis on Net
Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Beginner level

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Thermo Fisher Scientific Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel LibreOffice Calc
Mar 28, 2020 Dec 31, 2019 Sep 28, 2019 Jun 29, 2019 Mar 30, 2019 Dec 31, 2018 Sep 29, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jul 1, 2017 Apr 1, 2017 Dec 31, 2016 Oct 1, 2016 Jul 2, 2016 Apr 2, 2016 Dec 31, 2015 Sep 26, 2015 Jun 27, 2015 Mar 28, 2015
Short-term obligations and current maturities of long-term obligations 738  676  661  2,377  1,336  1,271  1,014  1,711  2,814  2,135  2,762  1,540  1,882  1,256  1,972  2,516  3,383  1,053  3,034  3,360  4,161 
Accounts payable 1,599  1,920  1,659  1,391  1,462  1,615  1,344  1,359  1,354  1,428  1,124  982  1,031  926  942  847  853  822  783  819  828 
Accrued payroll and employee benefits 755  1,010  883  809  704  982  817  755  643  918  771  613  521  709  611  522  421  598  549  479  487 
Contract liabilities 938  916  943  1,062  967  809  797  816  909  —  —  —  —  —  —  —  —  —  —  —  — 
Deferred revenue —  —  —  —  —  —  —  —  —  719  747  542  539  486  492  359  361  318  321  334  333 
Other accrued expenses 1,470  1,675  1,698  1,870  1,429  1,470  1,224  1,339  1,352  1,848  1,627  1,399  1,330  1,490  1,243  1,286  1,305  1,356  1,048  1,109  1,053 
Current liabilities 5,500  6,197  5,844  7,509  5,898  6,147  5,196  5,980  7,072  7,048  7,031  5,076  5,303  4,866  5,260  5,528  6,323  4,147  5,735  6,100  6,861 
Deferred income taxes 2,137  2,192  2,001  1,936  2,145  2,265  2,550  2,599  2,606  2,766  3,135  2,320  2,463  2,557  2,715  2,482  2,694  2,623  3,032  3,135  3,223 
Other long-term liabilities 3,261  3,241  3,137  3,133  3,048  2,515  2,682  2,670  2,657  2,569  1,887  1,470  1,464  1,573  1,437  1,348  1,359  1,295  1,252  1,196  1,162 
Long-term obligations, excluding current maturities 19,231  17,076  16,392  16,663  16,812  17,719  17,760  17,709  18,122  18,873  19,230  15,256  15,188  15,372  16,940  11,632  11,653  11,474  10,278  10,664  10,696 
Long-term liabilities 24,629  22,509  21,530  21,732  22,005  22,499  22,992  22,978  23,385  24,208  24,252  19,046  19,116  19,502  21,092  15,461  15,706  15,392  14,562  14,994  15,082 
Total liabilities 30,129  28,706  27,374  29,241  27,903  28,646  28,188  28,958  30,457  31,256  31,284  24,122  24,418  24,368  26,352  20,990  22,028  19,539  20,297  21,095  21,943 
Preferred stock, $100 par value; none issued —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Common stock, $1 par value 435  434  434  433  433  432  431  430  429  428  428  417  416  415  415  414  413  412  411  411  410 
Capital in excess of par value 15,186  15,064  14,964  14,887  14,771  14,621  14,526  14,408  14,319  14,177  14,112  12,328  12,252  12,140  12,097  12,017  11,919  11,801  11,733  11,669  11,607 
Retained earnings 22,791  22,092  21,165  20,482  19,439  18,696  17,866  17,226  16,542  15,914  15,446  14,972  14,419  13,927  13,357  12,943  12,485  12,142  11,600  11,184  10,732 
Treasury stock at cost (6,765) (5,236) (4,486) (4,443) (4,441) (3,665) (3,414) (3,128) (3,125) (3,103) (3,101) (3,070) (2,819) (2,306) (2,055) (2,027) (2,026) (1,008) (1,007) (989) (988)
Accumulated other comprehensive items (3,088) (2,679) (2,722) (2,630) (2,509) (2,498) (2,519) (2,491) (2,042) (2,003) (2,183) (2,256) (2,474) (2,636) (2,155) (2,082) (1,867) (1,997) (1,886) (1,595) (1,847)
Shareholders’ equity 28,559  29,675  29,355  28,729  27,693  27,586  26,890  26,445  26,123  25,413  24,702  22,392  21,795  21,539  21,659  21,264  20,924  21,350  20,850  20,680  19,915 
Total liabilities and shareholders’ equity 58,688  58,381  56,729  57,970  55,596  56,232  55,078  55,403  56,580  56,669  55,985  46,514  46,214  45,908  48,011  42,253  42,953  40,889  41,147  41,774  41,857 

Based on: 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-01), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-02), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-28), 10-Q (filing date: 2017-11-03), 10-Q (filing date: 2017-08-04), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-25), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Thermo Fisher Scientific Inc.’s current liabilities increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Thermo Fisher Scientific Inc.’s long-term liabilities increased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Thermo Fisher Scientific Inc.’s total liabilities increased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.
Shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Thermo Fisher Scientific Inc.’s shareholders’ equity increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.